Humacyte, Inc. (HUMA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Humacite first quarter results conference call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Instructions will follow at that time. As a reminder, this conference is being recorded. I will now turn the conference to call over to Tom Johnson with LifeSci Advisors. Please go ahead, sir. Thank you, Operator. Before we proceed with the call, we'd like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historic experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as a date hereof, and the company undertakes no obligation to update or revise the forward-looking statements except as required by law. Information presented on this call is contained in the press release we issued this morning and in our Form 10-Q, which after filing may be accessed from the investor page of the Hema site website. Joining me on today's call from Hema site are Dr. Laura Nicholson, President and Chief Executive Officer, Dale Sander, Chief Financial Officer, and Chief Corporate Development Officer, and BJ Sashley, Chief Commercial Officer. Dr. Nicholson will provide a summary of the company's progress for the first quarter and recent weeks, and Dale will review the financial results for the quarter ended March 31, 2025. Following their prepared remarks, BJ will join Laura...